FORT LAUDERDALE, Fla. and NATICK, Mass., Sept. 17, 2013 /PRNewswire/ -- OrbusNeich Medical Inc. and Boston Scientific Corporation (NYSE: BSX) have settled all stent-related litigation between the companies. The agreement resolves cases brought by the parties in Germany, the Netherlands, Ireland, the United Kingdom and the United States. The agreement, which includes a one-time payment from Boston Scientific to OrbusNeich, settles all stent-related disputes between the companies and does not include future financial obligations.
OrbusNeich is a global company that designs, develops, manufactures and markets innovative medical devices for the treatment of vascular diseases. Current products are the world's first dual therapy stent, the COMBO™ Dual Therapy Stent, and the world's first pro-healing stent, the Genous™ Stent. Other products include stents and balloons marketed under the names of Azule™, R stent, Scoreflex™, Sapphire™, Sapphire II and Sapphire NC. OrbusNeich is headquartered in Hong Kong and has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries. For more information, visit www.OrbusNeich.com.
About Boston Scientific
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 30 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare. For more information, visit www.bostonscientific.com and connect on Twitter and Facebook.
SOURCE OrbusNeich Medical Inc.; Boston Scientific Corporation